Gapping up
In reaction to strong earnings/guidance: LH +1%
M&A news: TPUB +60.9% (Gannett (GCI) proposes to acquire Tribune Publishing for $12.25/share in cash), BCS +1.3% (WSJ details that Carlyle Group (CG) might be among bidders for Barclays (BCS) Africa stake)
Other news: AVXL +17.9% (news special on a patient participating in Anavex's Azlheimer's trial taking place in Melbourne, Australia), SRPT +7% (shares currently halted - in conjunction with today's meeting with the FDA's Peripheral and Central Nervous System Drugs Advisory Committee), VRX +5.3% (receives additional notices of default under indentures due to delayed 10-K filing; notices do not accelerate any of the company's indebtedness), CPXX +3.3% (announces that patients treated in a Phase 2 clinical study with Vyxeos Liposome for Injection with newly diagnosed AML demonstrated 'reduced' healthcare resource use compared to conventional chemotherapy), SCWX +1.1% (still checking)
Analyst comments: JOY +1.5% (upgraded to Neutral from Sell at Goldman), CRH +1.2% (upgraded to Neutral from Underperform at BofA/Merrill), CAT +0.6% (upgraded to Neutral from Sell at Goldman)
In reaction to strong earnings/guidance: LH +1%
M&A news: TPUB +60.9% (Gannett (GCI) proposes to acquire Tribune Publishing for $12.25/share in cash), BCS +1.3% (WSJ details that Carlyle Group (CG) might be among bidders for Barclays (BCS) Africa stake)
Other news: AVXL +17.9% (news special on a patient participating in Anavex's Azlheimer's trial taking place in Melbourne, Australia), SRPT +7% (shares currently halted - in conjunction with today's meeting with the FDA's Peripheral and Central Nervous System Drugs Advisory Committee), VRX +5.3% (receives additional notices of default under indentures due to delayed 10-K filing; notices do not accelerate any of the company's indebtedness), CPXX +3.3% (announces that patients treated in a Phase 2 clinical study with Vyxeos Liposome for Injection with newly diagnosed AML demonstrated 'reduced' healthcare resource use compared to conventional chemotherapy), SCWX +1.1% (still checking)
Analyst comments: JOY +1.5% (upgraded to Neutral from Sell at Goldman), CRH +1.2% (upgraded to Neutral from Underperform at BofA/Merrill), CAT +0.6% (upgraded to Neutral from Sell at Goldman)